{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:43:19Z","timestamp":1777300999875,"version":"3.51.4"},"reference-count":63,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Descriptive values were determined for eight antifungal agents within the course of a multi\u2010centre study encompassing 1062 German and Austrian clinical yeast isolates. <jats:italic>Candida albicans<\/jats:italic> (54%) was the predominant species isolated followed by <jats:italic>Candida glabrata<\/jats:italic> (22%), <jats:italic>Candida parapsilosis<\/jats:italic> (6%), <jats:italic>Candida tropicalis<\/jats:italic> (5.7%), <jats:italic>Candida krusei<\/jats:italic> (4.3%), as well as eleven further candidal and four non\u2010<jats:italic>Candida<\/jats:italic> yeast species. While 519 (48.9%) isolates were tested susceptible to all antifungals tested, no isolate was found to exhibit complete cross resistance. For <jats:italic>C.\u2003albicans<\/jats:italic>, the proportions of susceptible isolates were 93.2% (amphotericin B), 95.6% (flucytosine), 84.3% (fluconazole), 83.8% (posaconazole), 91.8% (voriconazole), 96.5% (anidulafungin), 96.2% (caspofungin) and 97.6% (micafungin). Patterns of complete parallel resistances were observed within azoles (8.8%) and echinocandins (1.7%). While a decreased susceptibility was found infrequently for echinocandins and flucytosine, it was more common for azoles with highest proportions for isolates of <jats:italic>C.\u2003glabrata<\/jats:italic> (fluconazole, 40.6%; posaconazole, 37.2%)<jats:italic>, Candida guilliermondii<\/jats:italic> (fluconazole and posaconazole, each 25.0%), <jats:italic>C.\u2003krusei<\/jats:italic> (posaconazole, 28.3%; voriconazole, 60%), <jats:italic>C.\u2003parapsilosis<\/jats:italic> (fluconazole, 70.3%) and <jats:italic>C.\u2003tropicalis<\/jats:italic> (fluconazole, 62.3%). The descriptive values obtained in this study represent a valid basis for the comparison of recent and future epidemiological surveys to analyse the susceptibility of yeast isolates towards major antifungal substances.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2011.02165.x","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T07:13:44Z","timestamp":1326266024000},"source":"Crossref","is-referenced-by-count":45,"title":["Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi\u2010centre study"],"prefix":"10.1111","volume":"55","author":[{"given":"A. F.","family":"Schmalreck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Willinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lass\u2010Fl\u00f6rl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Fegeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Antifungal Susceptibility Testing (AFST) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0730-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm460"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/378745"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/322606"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01248-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/313756"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0768-0"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01551-06"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh504"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-06"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.008"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3107-3111.2004"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-8137.2003.00767.x"},{"key":"e_1_2_6_16_2","volume-title":"Medical Microbiology \u2013 Susceptibility Testing of Microbial Pathogens to Antimicrobial Agents \u2013 Part 84: Microdilution; Special Requirements for Testing of Fungi against Antifungal Agents","author":"Normenausschuss Medizin (NAMed) im DIN Deutsches Institut f\u00fcr Normung e.V DIN 58940\u201084:2002\u201010","year":"2002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01935.x"},{"key":"e_1_2_6_18_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Amphotericin B: Rationale for the clinical breakpoints version 1.0 2010.http:\/\/www.eucast.org[accessed 27 November 2011]."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01952-07"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01590-09"},{"key":"e_1_2_6_21_2","volume-title":"Rationale for Assessment Criteria for Minimum Inhibitory Concentration (MIC) and Inhibition Zone Diameter (IZD) of Fluconazole according to DIN 58940 for Clinically Relevant Yeasts, and Specification of Fluconazole Control Limits for Control Strains","author":"DIN\u2010Fachbericht 157:2007\u201012","year":"2007"},{"key":"e_1_2_6_22_2","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard; Third Informational Supplement, M27\u2010S3","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"e_1_2_6_23_2","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, M27\u2010A2","author":"Clinical and Laboratory Standards Institute","year":"2002"},{"key":"e_1_2_6_24_2","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard\u2010Third Edition, M27\u2010A3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01256-09"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg312"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00409-07"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1247"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430110089009"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00029-06"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/27.5.1138"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.04.006"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00046-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2009.01691.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.002"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1470-9465.2004.t01-1-00844.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2003.00883.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70218-8"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1103-y"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02434-08"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/634046"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg393"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00942-09"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.5.1782-1787.2006"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00937-08"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.917-921.2006"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1404.071083"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02117-09"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01128-10"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01811-10"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.01.002"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181760f42"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2003.00896.x"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1068-1071.2003"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2005.01154.x"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00432-7"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-06"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01901-07"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00566-08"},{"key":"e_1_2_6_60_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing.Anidulafungin: rationale for the clinical breakpoints version 1.0 2010.http:\/\/www.eucast.org[accessed 27 November 2011]."},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02087.x"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03646.x"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01899.x"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.01.004"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2011.02165.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2011.02165.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T15:19:02Z","timestamp":1697642342000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2011.02165.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,11]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1439-0507.2011.02165.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02165.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,11]]}}}